Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
The "Million Hearts" Initiative - Preventing Heart Attacks and Strokes
NEJM 365:e27, Frieden, T.R.,et al, 2011
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Early Coronary Revascularization Diminishes the Risk of Ischemic Stroke with Acute Myocardial Infarction
Stroke 37:2546-2551, vanDeGraaff,E.,et al, 2006
Addition of Clopidogrel to Aspirin in 45852 Patients With Acute Myocardial Infarction: Randomised Placebo-Controlled Trial
Lancet 366:1607-1621, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group, 2005
Homocysteine and Short-term Risk of Myocardial Infarction and Stroke in the Elderly
Arch Int Med 159:38-44, Bots,M.L.,et al, 1999
Prognosis of Patients with Symptomatic Vertebral or Basilar Artery Stenosis
WASID Study Group, Stroke 29:1389-13921998., , 1998
Ischemic Stroke After Acute Myocardial Infarction
Stroke 28:762-767, Mooe,T.,et al, 1997
Ventricular Dysfunction and the Risk of Stroke After Myocardial Infarction
NEJM 336:251-257, Loh,E.,et al, 1997
Risk of Stroke During Long-Term Anticoagulant Therapy in Patients After Myocardial Infarction
Ann Neurol 39:301-307, 2811996., Azar,A.J.,et al, 1996
Drugs and Surgery in the Prevention of Ischemic Stroke
NEJM 332:238-248, Barnett,H.J.M.,et al, 1995
Physical Activity and Stroke in British Middle Aged Men
BMJ 304:597-601, Wannamethee,G.&Shaper,A.G., 1992
Stroke Complic Acute MI, A Meta-Analysis of Risk Modific by Antigoac & Thrombolytic Therapy
Arch Int Med 152:2020-2024, Viatkus,P.T.,et al, 1992
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
NEJM 323:148-152, Smith,P.,et al, 1990
Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025
Left Atrial Appendage Occlusion and Its Role in Stroke Prevention
Stroke 56:1928-1937, Seiffge,D.J.,et al, 2025
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation
NEJM 392:2403-2412, 2473, Kharbanda,R.K.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients with Atrial Fibrillation,A Systematic Review and Meta-Analysis
JAMA Neurol 82:696-705, McCabe,J.J.,et al, 2025
The Role of GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists in Primary Stroke Prevention
Stroke 56:e307-e309, Inikori,E.,et al, 2025
The Multifactorial Nature of Ischemic Stroke in Malignancy
Stroke 56:e303-e306, Doyle,C.L.,et al, 2025
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Recurrent Ischemic Stroke in Patients with Atrial Fibrillation Whle Receiving Oral Anticoagulants
JAMA Neurol 81:805-813, Hindsholm,M.F.,et al, 2024
Optimal Timing of Anticoagulation after Acute Ischaemic Stroke with Atrial Fibrillation (OPTIMAS): A Multicentre, Blinded-Endpoint, Phase 4, Randomised Controlled Trial
Lancet 404:1731-1741, Werring,D.J.,et al, 2024
Does Capturing Debris During TAVR Prevent Strokes?
NEJM 387:1318-1319, Carroll, J.D. & Saver, J.L., 2022
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
NEJM 384:2081-2091,2154, Whitlock, R.P.,et al, 2021
Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors
Stroke 52:3121-3131, Grimaldi-Bensouda, L.,et al, 2021
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events with Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients with Atrial Fibrillation with a History of Intracranial Hemorrhage
JAMA Network Open 3:e206424, Tsai, C.T.,et al, 2020
Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Evidence-Based Management of Patent Foramen Ovale in Patients with Ischemic Stroke
JAMA Neurol 75:147-148, Kamel, H., 2018
Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies
BMJ 360:k1717, Adderley, N.J.,et al, 2018
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection on Undiagnosed Atrial Fibrillation
JAMA 320:146-155,139, Steinhubl, S.R.,et al, 2018
Improved Stroke Prevention in Atrial Fibrillation after the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 49:2122-2128, Forslund, T.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Optimal Timing of Anticoagulant Treatment after Intracerebral Hemorrhage in Patients with Atrial Fibrillation
Stroke 48:314-320, Pennlert, J.,et al, 2017
Benefits of Emergency Departments Contribution to Stroke Prophylaxis in Atrial Fibrillation
Stroke 48:1344-1352, Coll-Vinent, B.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Increasing Prevalence of Vascular Risk Factors in Patients with Stroke
Neurol 89:1985-1994, Otite, F.O.,et al, 2017
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Should Atrial Fibrillation Patients with only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?
Stroke 47:1831-1836, Fauchier, L.,et al, 2016